LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Computer Models Help to Develop Improved Gene Therapy Vectors

By LabMedica International staff writers
Posted on 29 Aug 2013
Image: Electron micrograph of adeno-associated viruses (AAVs) (Photo courtesy of Dr. Graham Beards at en.wikipedia).
Image: Electron micrograph of adeno-associated viruses (AAVs) (Photo courtesy of Dr. Graham Beards at en.wikipedia).
Investigators in the field of gene therapy have used an advanced computer algorithm to predict how different adeno-associated viruses (AAVs) can be combined to form the optimum carriers of therapeutic genetic material.

AAVs are small viruses that infect humans and some other primate species. AAVs are not currently known to cause disease, and the virus induces a very mild immune response. Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell. These features make AAV an attractive candidate for creating viral vectors for gene therapy.

To develop quantitative design principles for guiding site-directed recombination of AAV capsids, investigators at Rice University (Houston, TX, USA) examined how capsid structural perturbations predicted by the SCHEMA algorithm correlated with experimental measurements of disruption in 17 chimeric capsid proteins.

They reported in the July 31, 2013, online addition of journal ACS Synthetic Biology that in a chimera population created by recombining AAV serotypes two and four, protection of viral genomes and cellular transduction were inversely related to calculated disruption of the capsid structure. The investigators did not observe a correlation between genome packaging and calculated structural disruption; a majority of the chimeric capsid proteins formed at least partially assembled capsids and more than half-packaged genomes, including those with the highest SCHEMA disruption. Thus, the SCHEMA algorithm should be useful for delineating quantitative design principles to guide the creation of libraries enriched in genome-protecting virus nanoparticles that can effectively transduce cells.

“Gene therapy shows promise in the treatment of not only genetic disorders but also cancer and cardiovascular diseases,” said senior author Dr. Junghae Suh, assistant professor of bioengineering at Rice University. “But you need a mechanism to get the correct gene into the human body and to the target cells. To do that, people use gene vectors, and viruses encompass the largest category of vectors. They have naturally evolved to deliver genes into the body. Our goal is to reprogram them to target specific organs or tissues.”

“The big challenge is to go about this in a rational manner,” said Dr. Suh. “People have done a lot of work to solve the structure of viruses. We know what they look like. The question is: How can we use that information to guide the design of our viral vectors?”

Related Links:
Rice University

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more